What Does Wall Street Think About Pharvaris N.V. (PHVS)?

Core Insights - Pharvaris N.V. (NASDAQ:PHVS) is highlighted as a promising small-cap stock with significant upside potential, receiving a Buy rating from Morgan Stanley with a price target of $41 and an Outperform rating from Oppenheimer with a raised target of $50 from $44 [1][2]. Group 1: Clinical Study Results - The pivotal RAPIDe-3 study demonstrated positive top-line results for deucrictibant, confirming its potential for on-demand treatment of HAE attacks, with a median time to onset of symptom relief of 1.28 hours, significantly faster than placebo [2]. - All secondary efficacy endpoints were achieved, including a median End of Progression time of 17.47 minutes and complete symptom resolution in a median of 11.95 hours, confirming the safety profile of deucrictibant across various HAE subtypes and attack severities [3]. Group 2: Future Plans - Pharvaris N.V. plans to use data from the pivotal Phase 3 study as the basis for marketing authorization applications, which are expected to be filed in the first half of 2026 [4].